Immunservice is a biopharmaceutical company founded in 2007, focusing on orphan disease indications and large market indication areas with high unmet medical need. The company's unique biomimetic approach translates human immune hormones into well-tolerated and highly effective marketable drugs, enhancing patient survival and quality of life.
Their biomimetic therapy holds significant potential to cure patients with cancer, including those with urgent needs and limited treatment alternatives. With the last investment being a Series C investment on 18th February 2015, Immunservice received funding from HTGF (High-Tech Gruenderfonds).
Immunservice operates in the biotechnology and developer tools industries, addressing critical medical needs with its innovative pharmaceutical solutions. Their approach and focus on addressing orphan diseases set them apart as a compelling investment opportunity within the biopharmaceutical sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | Unknown | 1 | HTGF | High-Tech Gruenderfonds | 18 Feb 2015 |
| Seed Round | Unknown | 1 | HTGF | High-Tech Gruenderfonds | 21 Jan 2008 |
No recent news or press coverage available for Immunservice.
We care about your data, and we'd love to use cookies make your experience better.